144 related articles for article (PubMed ID: 37658272)
1. The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy.
Blumencranz P; Habibi M; Shivers S; Acs G; Blumencranz LE; Yoder EB; van der Baan B; Menicucci AR; Dauer P; Audeh W; Cox CE
Ann Surg Oncol; 2023 Dec; 30(13):8353-8361. PubMed ID: 37658272
[TBL] [Abstract][Full Text] [Related]
2. Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer.
Pellicane JV; Beitsch PD; Rock DT; Budway RJ; Dul CL; Kelemen PR; Ashikari AY; Baron PL; Weinstein PD; Mislowsky A; Lee LA; Beatty J; Murray MK; Dupree BB; Finn C; Corcoran K; Wang S; Menicucci AR; Yoder EB; Blumencranz LE; Dauer P; Audeh W; Whitworth PW;
Surg Oncol; 2022 Dec; 45():101885. PubMed ID: 36436423
[TBL] [Abstract][Full Text] [Related]
3. Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy.
Whitworth PW; Beitsch PD; Murray MK; Richards PD; Mislowsky A; Dul CL; Pellicane JV; Baron PL; Rahman RL; Lee LA; Dupree BB; Kelemen PR; Ashikari AY; Budway RJ; Lopez-Penalver C; Dooley W; Wang S; Dauer P; Menicucci AR; Yoder EB; Finn C; Blumencranz LE; Audeh W
JCO Precis Oncol; 2022 Sep; 6():e2200197. PubMed ID: 36108259
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes.
Cao L; Sugumar K; Keller E; Li P; Rock L; Simpson A; Freyvogel M; Montero AJ; Shenk R; Miller ME
Ann Surg Oncol; 2021 Oct; 28(10):5730-5741. PubMed ID: 34342757
[TBL] [Abstract][Full Text] [Related]
5. Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and BluePrint to guide preoperative systemic treatment decisions.
Göker E; Hendriks MP; van Tilburg M; Barcaru A; Mittempergher L; van Egmond A; Kleijn M; Generali D;
Eur J Cancer; 2022 May; 167():92-102. PubMed ID: 35421703
[TBL] [Abstract][Full Text] [Related]
6. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
[TBL] [Abstract][Full Text] [Related]
7. Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
Whitworth P; Stork-Sloots L; de Snoo FA; Richards P; Rotkis M; Beatty J; Mislowsky A; Pellicane JV; Nguyen B; Lee L; Nash C; Gittleman M; Akbari S; Beitsch PD
Ann Surg Oncol; 2014 Oct; 21(10):3261-7. PubMed ID: 25099655
[TBL] [Abstract][Full Text] [Related]
8. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.
Tadros AB; Yang WT; Krishnamurthy S; Rauch GM; Smith BD; Valero V; Black DM; Lucci A; Caudle AS; DeSnyder SM; Teshome M; Barcenas CH; Miggins M; Adrada BE; Moseley T; Hwang RF; Hunt KK; Kuerer HM
JAMA Surg; 2017 Jul; 152(7):665-670. PubMed ID: 28423171
[TBL] [Abstract][Full Text] [Related]
9. Nodal downstaging as a treatment goal for node-positive pancreatic cancer.
Portuondo JI; Massarweh NN; Zhang Q; Chai CY; Tran Cao HS
Surgery; 2019 Jun; 165(6):1144-1150. PubMed ID: 30745009
[TBL] [Abstract][Full Text] [Related]
10. Genomic profiling of breast cancer in African-American women using MammaPrint.
Nunes RA; Wray L; Mete M; Herbolsheimer P; Smith KL; Bijelic L; Boisvert ME; Swain SM
Breast Cancer Res Treat; 2016 Oct; 159(3):481-8. PubMed ID: 27568021
[TBL] [Abstract][Full Text] [Related]
11. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy.
Glück S; de Snoo F; Peeters J; Stork-Sloots L; Somlo G
Breast Cancer Res Treat; 2013 Jun; 139(3):759-67. PubMed ID: 23756626
[TBL] [Abstract][Full Text] [Related]
12. How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery?
Montagna G; Sevilimedu V; Fornier M; Jhaveri K; Morrow M; Pilewskie ML
Ann Surg Oncol; 2020 Nov; 27(12):4702-4710. PubMed ID: 32839900
[TBL] [Abstract][Full Text] [Related]
13. Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy.
Bayraktar S; Royce M; Stork-Sloots L; de Snoo F; Glück S
Med Oncol; 2014 Oct; 31(10):163. PubMed ID: 25186065
[TBL] [Abstract][Full Text] [Related]
14. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
15. A nationwide registry-based cohort study of the MammaPrint genomic risk classifier in invasive breast cancer.
Groenendijk FH; Jager A; Cardoso F; van Deurzen CHM
Breast; 2018 Apr; 38():125-131. PubMed ID: 29310037
[TBL] [Abstract][Full Text] [Related]
16. Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer.
Whitworth P; Beitsch PD; Pellicane JV; Baron PL; Lee LA; Dul CL; Nash CH; Murray MK; Richards PD; Gittleman M; Budway R; Rahman RL; Kelemen P; Dooley WC; Rock DT; Cowan K; Lesnikoski BA; Barone JL; Ashikari AY; Dupree B; Wang S; Menicucci AR; Yoder EB; Finn C; Corcoran K; Blumencranz LE; Audeh W;
Ann Surg Oncol; 2022 Apr; 29(7):4141-52. PubMed ID: 35378634
[TBL] [Abstract][Full Text] [Related]
17. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
Kuerer HM; Sahin AA; Hunt KK; Newman LA; Breslin TM; Ames FC; Ross MI; Buzdar AU; Hortobagyi GN; Singletary SE
Ann Surg; 1999 Jul; 230(1):72-8. PubMed ID: 10400039
[TBL] [Abstract][Full Text] [Related]
18. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
Piccart M; van 't Veer LJ; Poncet C; Lopes Cardozo JMN; Delaloge S; Pierga JY; Vuylsteke P; Brain E; Vrijaldenhoven S; Neijenhuis PA; Causeret S; Smilde TJ; Viale G; Glas AM; Delorenzi M; Sotiriou C; Rubio IT; Kümmel S; Zoppoli G; Thompson AM; Matos E; Zaman K; Hilbers F; Fumagalli D; Ravdin P; Knox S; Tryfonidis K; Peric A; Meulemans B; Bogaerts J; Cardoso F; Rutgers EJT
Lancet Oncol; 2021 Apr; 22(4):476-488. PubMed ID: 33721561
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67.
Boughey JC; Hoskin TL; Goetz MP
Ann Surg Oncol; 2022 Sep; 29(9):5747-5756. PubMed ID: 35569077
[TBL] [Abstract][Full Text] [Related]
20. The differential effect of neoadjuvant chemotherapy and chemoradiation on nodal downstaging in pancreatic adenocarcinoma.
Altimari M; Wells A; Abad J; Chawla A
Pancreatology; 2023 Nov; 23(7):805-810. PubMed ID: 37599170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
